Rhumbline Advisers Atea Pharmaceuticals, Inc. Transaction History

Rhumbline Advisers

  • $113 Billion
  • Q2 2025

A detailed history of Rhumbline Advisers transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 119,420 shares of AVIR stock, worth $354,677. This represents 0.0% of its overall portfolio holdings.

Number of Shares
119,420
Previous 116,443 2.56%
Holding current value
$354,677
Previous $348,000 23.28%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 12, 2025
BUY
$2.55 - $3.6 $7,591 - $10,717
2,977 Added 2.56%
119,420 $429,000
Q1 2025

Apr 08, 2025
SELL
$2.9 - $3.52 $38,723 - $47,002
-13,353 Reduced 10.29%
116,443 $341,000
Q4 2024

May 29, 2025
BUY
$2.93 - $3.82 $39,124 - $51,008
13,353 Added 11.47%
129,796 $434,000
Q4 2024

Jan 30, 2025
SELL
$2.93 - $3.82 $9,721 - $12,674
-3,318 Reduced 2.49%
129,796 $434,000
Q3 2024

Nov 12, 2024
SELL
$3.17 - $4.02 $14,214 - $18,025
-4,484 Reduced 3.26%
133,114 $445,000
Q2 2024

Aug 01, 2024
SELL
$3.31 - $4.04 $14,246 - $17,388
-4,304 Reduced 3.03%
137,598 $455,000
Q1 2024

May 09, 2024
SELL
$3.09 - $4.56 $16,111 - $23,775
-5,214 Reduced 3.54%
141,902 $573,000
Q4 2023

Feb 08, 2024
BUY
$2.8 - $3.35 $35,862 - $42,906
12,808 Added 9.54%
147,116 $448,000
Q3 2023

Nov 09, 2023
SELL
$3.0 - $3.79 $20,241 - $25,571
-6,747 Reduced 4.78%
134,308 $402,000
Q2 2023

Aug 08, 2023
BUY
$3.21 - $5.06 $55,751 - $87,882
17,368 Added 14.04%
141,055 $527,000
Q1 2023

May 11, 2023
BUY
$3.0 - $4.97 $16,782 - $27,802
5,594 Added 4.74%
123,687 $414,000
Q4 2022

Feb 14, 2023
BUY
$4.35 - $6.17 $8,608 - $12,210
1,979 Added 1.7%
118,093 $568,000
Q3 2022

Nov 10, 2022
BUY
$5.49 - $8.79 $35,146 - $56,273
6,402 Added 5.84%
116,114 $661,000
Q2 2022

Aug 11, 2022
BUY
$5.33 - $8.18 $146,441 - $224,745
27,475 Added 33.41%
109,712 $779,000
Q1 2022

May 12, 2022
SELL
$5.5 - $9.19 $22,011 - $36,778
-4,002 Reduced 4.64%
82,237 $594,000
Q4 2021

Feb 10, 2022
BUY
$7.67 - $44.59 $4,195 - $24,390
547 Added 0.64%
86,239 $771,000
Q3 2021

Nov 12, 2021
BUY
$21.33 - $35.06 $76,702 - $126,075
3,596 Added 4.38%
85,692 $3 Million
Q2 2021

Aug 05, 2021
BUY
$19.22 - $59.08 $1.25 Million - $3.84 Million
64,933 Added 378.33%
82,096 $1.76 Million
Q1 2021

May 06, 2021
BUY
$41.42 - $88.44 $192,478 - $410,980
4,647 Added 37.13%
17,163 $1.06 Million
Q4 2020

Feb 10, 2021
BUY
$26.36 - $41.78 $329,921 - $522,918
12,516 New
12,516 $523,000

Others Institutions Holding AVIR

# of Institutions
110
Shares Held
48.9M
Call Options Held
0
Put Options Held
0
View Full List

About Atea Pharmaceuticals, Inc.

AVIR Quotes by TradingView
  • Ticker AVIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,258,600
  • Market Cap $247M
  • Description
  • Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...
More about AVIR
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email